YOLFTbeta
Fusion Antibodies PLC

Fusion Antibodies PLC

FAB · LSE · Healthcare / Biotechnology

4.25GBX+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close4.25
Open4.25
Day Range3.94 – 4.25
52-Week Range9.00 – 20.00
Volume951.15K
Market Cap14.08M
P/E (TTM)0.00
Forward P/E243.90
EPS-0.01
Dividend Yield0.00%
Beta1.24
50-Day Avg11.00
200-Day Avg12.65

About

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing and engineering, antibody humanization and rational affinity maturation platform, recombinant protein expressions, and stable cell line development and cGMP scale up services. Its products are used in the pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company has a collaboration agreement with the National Cancer Institute for the use of OptiMAL. Fusion Antibodies plc was incorporated in 2000 and is based in Belfast, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Adrian Robert Kinkaid Ph.D.
  • Employees27
  • HeadquartersSpringbank Industrial Estate, Belfast, United Kingdom, BT17 0QL, UK
  • Websitehttps://www.fusionantibodies.com

Leadership

  • Dr. Adrian Robert Kinkaid Ph.D.CEO & Director · b. 1967
  • Dr. Richard John Buick Ph.D.Chief Scientific Officer & Director · b. 1976
  • Mr. Stephen Barry SmythCompany Secretary, Interim CFO & Director · b. 1974
  • Ms. Nicola HamiltonOperations Manager

Financials

Income Statement

Currency: GBP2013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Revenue405.00K723.05K909.29K1.48M1.91M2.69M2.18M3.90M4.17M4.80M2.90M1.14M1.97M2.11M
Growth (%)-+78.53%+25.76%+62.90%+29.21%+40.59%-18.91%+78.52%+6.93%+15.22%-39.55%-60.84%+72.98%+7.38%
Cost of Revenue350.47K369.27K460.44K618.05K952.46K1.21M1.38M2.74M2.85M3.08M2.70M1.40M1.53M1.01M
Gross Profit54.52K353.77K448.85K863.21K961.50K1.48M804.00K1.15M1.31M1.72M202.00K-265.00K430.00K1.10M
Gross Margin13.46%48.93%49.36%58.28%50.24%55.13%36.85%29.58%31.45%35.78%6.96%-23.33%21.88%52.32%
Operating Expense527.74K473.20K547.64K835.52K834.97K1.42M2.31M2.27M2.69M3.05M3.04M2.02M2.21M3.08M
Operating Income-473.22K-119.43K-98.79K27.68K126.53K62.39K-1.51M-1.11M-1.38M-1.33M-2.83M-2.29M-1.78M-1.98M
Operating Margin-116.84%-16.52%-10.86%1.87%6.61%2.32%-69.14%-28.60%-33.11%-27.76%-97.66%-201.41%-90.53%-93.89%
EBITDA-444.75K-101.09K-79.35K49.92K288.47K-636.88K-1.06M-431.00K-532.00K-573.00K-2.48M-2.06M-1.62M-1.85M
EBITDA Margin-109.82%-13.98%-8.73%3.37%15.07%-23.67%-48.79%-11.07%-12.77%-11.94%-85.59%-181.78%-82.65%-87.87%
Net Income-468.74K-113.54K-85.11K1.15M119.95K-699.94K-1.26M-697.00K-2.90M-1.20M-2.60M-2.23M-1.71M-1.15M
Net Income Margin-115.74%-15.70%-9.36%77.91%6.27%-26.01%-57.95%-17.89%-69.60%-25.01%-89.49%-195.95%-87.18%-54.45%
R&D199.92K160.94K--70.00K69.00K240.00K391.00K613.00K699.00K806.00K254.00K191.00K861.00K
R&D as % of Total Revenue49.36%22.26%--3.66%2.56%11.00%10.04%14.72%14.57%27.78%22.36%9.72%40.81%
Interest Expense4271.06K6654966154.86K4.00K20.00K18.00K9.00K4.00K5.00K3.00K20.00K
Interest Expense % of Total Revenue0.11%0.15%0.07%0.03%0.03%0.18%0.18%0.51%0.43%0.19%0.14%0.44%0.15%0.95%

Balance Sheet

Currency: GBP2006-03-312007-03-312008-03-312009-03-312010-03-312011-03-312012-03-312013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Assets494.00K1.05M1.12M821.00K819.00K705.00K370.00K303.69K313.89K370.96K1.87M2.16M7.21M6.24M6.04M5.83M4.92M2.06M2.42M1.32M2.73M
Total Liabilities290.00K447.00K462.00K633.00K305.00K382.00K443.00K253.56K297.57K201.67K411.43K450.22K633.59K888.53K1.23M1.08M1.23M939.00K627.00K654.00K1.10M
Total Equity204.00K608.00K655.00K188.00K515.00K323.00K-30.13K-3.68K169.29K1.46M1.71M6.58M5.35M4.81M4.75M3.68M1.12M1.79M669.00K1.62M
Cash62.00K165.00K437.00K128.00K318.00K126.00K45.00K129.03K139.09K103.63K413.94K285.69K4.49M1.98M1.54M2.69M2.05M195.00K1.20M359.00K1.04M
Total Debt------------120.82K139.18K380.00K230.00K69.00K75.00K43.00K20.00K331.00K
Net Debt--------129.03K-139.09K-103.63K-413.94K-285.69K-4.37M-1.85M-1.16M-2.46M-1.98M-120.00K-1.16M-339.00K-712.00K

Cash Flow

Currency: GBP2013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Operating Cash Flow---182.05K346.57K-37.37K77.19K-1.10M-166.00K-1.15M-330.00K-1.75M-1.77M-1.36M-1.11M
Investing Cash Flow---11.20K-35.76K-90.27K-444.60K-1.38M-109.00K-365.00K-258.00K-114.00K1.00K-5.00K-60.00K
Financing Cash Flow--157.79K-496-6154.57M-27.67K-172.00K2.67M-46.00K7.00K2.77M529.00K1.85M
Capital Expenditure0011.20K35.76K90.27K444.60K1.38M109.00K365.00K258.00K114.00K2.00K10.00K60.00K
Free Cash Flow---193.25K310.81K-127.64K-367.40K-2.48M-275.00K-1.52M-591.00K-1.87M-1.77M-1.37M-1.17M
FCF to OCF--106.15%89.68%341.53%-475.96%225.70%165.66%131.71%179.09%106.50%100.11%100.73%105.41%

Earnings

Report DateNov 4, 2016May 4, 2017Dec 18, 2017Aug 16, 2018Nov 26, 2018Aug 14, 2019Dec 2, 2019Aug 19, 2020Nov 20, 2020Aug 16, 2021Dec 6, 2021Sep 1, 2022Dec 5, 2022Sep 29, 2023Nov 19, 2024May 28, 2025Sep 4, 2025Nov 24, 2025Jun 3, 2026
EPS Estimate0.000.000.000.000.000.000.000.000.00-----4.300.000.000.000.000.00
EPS Actual0.000.00-0.01-0.05-0.03-0.06-0.02-0.01-0.02-0.09-0.02-0.02-0.040.00-0.010.00-0.01-0.010.00
Surprise-------------100.00%-----
Timing-----------After-hoursPre-marketPre-market-----

Key Statistics & Ratios

Market Cap14.08M
Enterprise Value13.31M
Trailing P/E0.00
Forward P/E243.90
Price / Sales6.67
Price / Book8.64
EPS-0.01
Book Value0.013
Revenue (TTM)2.11M
Gross Profit (TTM)1.23M
EBITDA-1.06M
Profit Margin-54.46%
Operating Margin-44.73%
Return on Equity-96.64%
Return on Assets-33.52%
Shares Outstanding125.16M
Shares Float110.05M
Beta1.24
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%